Revolutionize cell therapies with our MSC bio-carrier platform
precision therapies for a variety of conditions, including cancer, osteoarthritis, and regenerative medicine.
Scroll down to learn more ↓
Improving patient outcomes across multiple therapeutic areas
Our platform enables precision therapies for a variety of conditions, including cancer, osteoarthritis, and regenerative medicine.
Our Platform
We use AD-MSCs to safely and effectively deliver:
Oncolytic Viruses: Targeted viral therapies for cancer treatment.
Anti-Inflammatory Agents: Solutions for chronic inflammatory conditions.
Our Vision
CellVira aims to revolutionize cell-based therapies by advancing our MSC bio-carrier platform, improving patient outcomes across multiple therapeutic areas.
Key Benefits
Personalized Treatments: Autologous cell use ensures high safety and efficacy.
Scalable Solutions: Our platform is adaptable for both clinical and commercial applications.
About Us
CellVira, a subsidiary of Orgenesis Inc., is a biotechnology company based in Maryland, USA, specializing in autologous adipose-derived mesenchymal stem cell (AD-MSC)-based therapies. We utilize MSCs as bio-carriers to deliver oncolytic viruses and anti-inflammatory agents, offering a scalable and patient-specific platform for a range of therapeutic applications.